WISP-2 in human gastric cancer and its potential metastatic suppressor role in gastric cancer cells mediated by JNK and PLC-\(\gamma\) pathways

Jiafu Ji *,1,2, Shuqin Jia2,3, Yongning Jia1,2, Ke Ji2, Rachel Hargest2 and Wen G Jiang *,2

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52, Beijing 100142, China; 2Cardiff University-Peking University Cancer Institute, Cardiff University School of Medicine, Cardiff, UK and 3Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Laboratory of Molecular Oncology, Peking University Cancer Hospital and Institute, No. 52, Beijing 100142, China

Background: It has recently been shown that WISP proteins (Wnt-inducted secreted proteins), a group of intra- and extra-cellular regulatory proteins, have been implicated in the initiation and progression of a variety of tumour types including colorectal and breast cancer. However, the role of WISP proteins in gastric cancer (GC) cells and their clinical implications have not yet been elucidated.

Methods: The expression of WISP molecules in a cohort of GC patients was analysed using real-time quantitative PCR and immunohistochemistry. The expression of a panel of recognised epithelial–mesenchymal transition (EMT) markers was quantified using Q-PCR in paired tumour and normal tissues. WISP-2 knockdown (kd) sublines using ribozyme transgenes were created in the GC cell lines AGS and HGC27. Subsequently, several biological functions, including cell growth, adhesion, migration and invasion, were studied. Potential pathways for the interaction of EMT, extracellular matrix and MMP were evaluated.

Results: Overexpression of WISP-2 was detected in GC and significantly correlated with early tumour node-metastasis staging, differentiation status and positively correlated with overall survival and disease-free survival of the patients. WISP-2 expression was inversely correlated with that of Twist and Slug in paired samples. Kd of WISP-2 expression promoted the proliferation, migration and invasion of GC cells. WISP-2 suppressed GC cell metastasis through reversing EMT and suppressing the expression and activity of MMP9 and MMP2 via JNK and ERK. Cell motility analysis indicated that WISP-2 kd contributed to GC cells' motility and can be attenuated by PLC-\(\gamma\) and JNK small inhibitors.

Conclusions: Increased expression of WISP-2 in GC is positively correlated with favourable clinical features and the survival of patients with GC and is a negative regulator of growth, migration and invasion in GC cells. These findings suggest that WISP-2 is a potential tumour suppressor in GC.

The multistep process of tumour development involves the cell acquiring new phenotypic traits, including overriding growth controls, induction of angiogenesis, evasion from host anti-tumour responses, extravasation and growth at metastatic sites under the influence of successive genetic alterations and environmental factors. In patients with solid tumours, the main cause of death is not the primary neoplasm, but metastases in the vital organs (Leber and Efferth, 2009). The overall growth behaviour of a developing neoplasm is a net result of the combined kinetic interactions between heterogenous tumour cells.
and the host. Intriguingly, the dominant influence of migration on tumour growth is dependent on the balance between tumour cell proliferation and death (Endersling et al., 2009). During the development of metastases, a number of processes occur, including epithelial–mesenchymal transition (EMT), migration and invasion, anoikis resistance, extravasation and organ colonisation.

WISP proteins (WNT1-inducible signalling pathway proteins) are a subfamily of the CCN super family (Pennica et al., 1998). The CCN family of proteins is a crucial group of signalling molecules found in eukaryotic organisms. The first three members of the family are Cyr61 (cysteine-rich protein 61), connective tissue growth factor and NOV (nephroblastoma overexpressed gene; Bork, 1993), which are now designated as CCN1, CCN2 and CCN3. There are three other family members WISP-1, WISP-2 and WISP-3, which are designated as CCN4, CCN5 and CCN6 (Brickstock, 2003). It has been shown that WISP proteins are upregulated in Wnt-1-transformed cells (Pennica et al., 1998).

As a part of the extracellular matrix (ECM), WISP proteins modulate various cellular activities, such as cell growth, differentiation, invasion, migration and survival (Chen and Lau, 2009). WISP-1 expression has been found in several cell types and implicated in cellular and tissue homeostasis through a variety of autocrine and paracrine loops, thereby representing a highly attractive target for therapeutic applications. Elevated WISP-1 expression has recently been reported in several cancers, including hepatocellular carcinoma (Calvisi et al., 2005), colon adenocarcinoma (Tian et al., 2007; Davies et al., 2010), lung carcinoma (Soon et al., 2003; Chen et al., 2007) and breast cancer (Xie et al., 2001; Davies et al., 2007). However, the functional mechanisms of WISP-1 in tumour development and progression are still controversial. The structural difference between WISP-2 and other WISP members is the absence of the carboxyl-terminal domain (Brigstock, 2003; Davies et al., 2010). WISP-2 has been related to tumorigenesis and malignant transformation, especially in breast cancer (Zoubine et al., 2001; Davies et al., 2007), colorectal cancer (Davies et al., 2010) and hepatocellular carcinoma (Cervello et al., 2004). However, it appears that the WISP-2 functions are tissue-specific and influenced by the tumour microenvironment. Furthermore, it has been speculated that WISP-2 acts as a dominant negative regulator of other CCN family members, because of its structural difference from other WISP members. WISP-3 is the least-studied WISP member, which is a secreted protein that modulates the insulin-like growth factor-1 signalling pathway. WISP-3 was found to have tumour growth, proliferation and invasion inhibitory functions in inflammatory breast cancer and aggressive non-inflammatory breast cancer (Lorenzatti et al., 2011).

Clinical studies have revealed differential WISP expression profiles among different types of tumours along with different functions. The discordant results obtained from different cancers have raised uncertainty as to the role of WISP in carcinogenesis and metastasis per se. It has become apparent that the relative abundance of individual WISPs members, which often have contradictory activities, has a net effect on tumour progression. It has also been suggested that the relative abundance of WISP-1, WISP-2 and WISP-3 may be harnessed for a novel therapeutic approach to highly invasive cancers.

In this study, we determined the expression of WISP family members at both mRNA and protein levels in gastric cancer (GC) specimens and their adjacent normal tissues, as well as in different GC cell lines. Our data showed that WISP family members have different expression profiles in GC. Moreover, in vitro studies suggest loss of WISP-2 signalling may be a crucial permissive event for EMT and ECM degradation and cell migration.

**Materials and Methods**

**Chemicals.** We purchased the following materials from Life Technologies (Paisley, Scotland, UK): PCR primers, molecular-biology-grade agarose, DNA ladder, ePef6/V5-TOPO plasmid vector and competent One Shot TOP10 E. coli. We obtained the Mastermix for routine PCR and quantitative PCR from Thermo Fisher Scientific (Surrey, UK). WISP-1, 2 and 3 antibodies were purchased from Abgent Inc. (Atlanta, GA, USA; Cat Number: AP6255a, AP6256a and AP6257a). Anti-GAPDH antibody was from Santa Cruz Biotechnologies Inc (Santa Cruz, CA, USA). A potent PLC-γ-specific inhibitor known as STK-870702 or known as 3-amino-N-((3-chlorophenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b] quinoline-2-carboxamide, derived from thieno [2,3-b] pyridine, was purchased from Vitas-M Laboratory, Ltd (Apeldoorn, The Netherlands; Cat number: STK870702; Feng et al., 2012; Leung et al., 2014) and a generic PLC inhibitor, U73122 was from Tocris Bioscience (Bristol, UK). The FAK inhibitor (PF573228, Cat Number: 3239) was from Tocris Bioscience; JNKII inhibitor (SP600125, Cat Number: 420119) was from Merck (Darmstadt, Germany); N-WASP inhibitor (Wiskostatin, Cat Number: 681525) was from Calbiochem (Watford, Herts, UK). The MMP9 inhibitor (Marimastat, Cat number: 2631) and MMP2 inhibitor (ARP100, Cat number: 2621) were both from Tocris Bioscience; Matrixel was from BD Bio-Science (Oxford, UK; Cat Number: 354234). ECIS 96W1E+ arrays and culturewares were from Applied Biophysics Inc. (ECIS, Troy, NY, USA). TRI Reagent was from Sigma (Sigma-Aldrich, Inc., Poole, UK) and first strand cDNA was synthesised using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

**Human gastric tumour tissues.** A total of 324 patients (male 231, female 93; mean age 59.8 years; range 23–87 years: median survival 24 months) with GC, who were diagnosed and surgically treated at the Peking University Cancer Hospital between 2004 and 2007, were enrolled in this study. The study was approved by the local ethics committee (Ethics Number: 2006021) and consent was obtained from patients. Some of the patients had received chemotherapy or radiation therapy preoperatively. The following histopathological information was collected: depth of tumour invasion, histological grade, status of lymph node metastasis, presence or absence of liver metastases and vascular invasion. Staging of GC was classified according to the 1997 tumour node-metastasis (TNM) classification recommended by the International Union Against Carcinoma. All patients were followed up until June 2012.

**Gastric cancer cell lines.** Two gastric cell lines, AGS and HGC27, were acquired from the European Collection of Animal Cell Culture (Salisbury, UK). Cells were maintained in DMEM-F12 medium supplemented with 10% fetal bovine serum and antibiotics.

**RNA extraction and RT-PCR.** A measure of 50–100 mg of frozen tissue or cells from a 25-cm² culture flask were homogenised and placed into 1 ml of TRI reagent for RNA extraction. The homogenate was then precipitated with chloroform and isopropyl alcohol. The resultant RNA pellet was resuspended in DEPC water. The concentration of RNA was determined using a UV spectrophotometer. First strand cDNA was synthesised using iScript cDNA Synthesis Kit, and the quality of the cDNA was verified using GAPDH primers. PCR was performed using GreenTaq ReadyMix PCR reaction mix. Cycling conditions were 94°C for 5 min, followed by 28–30 cycles at 94°C for 30 s, 55°C for 30 s and 72°C for 40 s. This was followed by a final extension of 10 min at 72°C. The products were visualised in 1–2% agarose gels stained

![Image](https://via.placeholder.com/150)
with SYBR green. All the primers used in this study are listed in Supplementary Table 1.

**Western blotting.** Cells were lysed by sonication in lysis buffer at 4°C. Lysates were centrifuged, supernatants were collected and total protein concentrations were determined by the BCA reagent assay (Pierce, Paisley, Scotland, UK). Western blot analysis was performed on 10% SDS-PAGE gel and transfer onto nitrocellulose membranes. The WISP-2 protein was detected with anti-WISP-2 antibody (1:200) using a SNAP-id 2.0 machine (Millipore, Watford, Herts, UK). Resultant western blot bands were normalised against GAPDH (1:5000).

**Quantitative analysis of WISP family members and EMT markers in tissues.** The mRNA levels of WISP-1, WISP-2, WISP-3 and the EMT markers (E-cadherin, Slug and Twist), in the cDNA prepared as above, were determined by real-time quantitative PCR using Amplifluor technology (Nazarenko et al, 2003). Cytokeratin-19 was used as a control during the 96 cycles of analysis. Primer details are given in Table 1. The reaction was carried out under the following conditions: 94°C for 5 min, 96 cycles at 94°C for 15 s, 55°C for 35 s and 72°C for 20 s. The levels of the transcripts were generated using an internal standard that was simultaneously amplified with the samples, and the results are shown in two ways: levels of transcripts based on equivalent amounts of mRNA and as a target/cytokeratin-19 ratio (Davies et al., 2010).

**Immunohistochemical staining of WISP family proteins.** Immunohistochemistry was performed in 316 cases of pathological sections. Sections of 4 μm thickness, prepared from formalin-fixed, paraffin-embedded tissues were mounted on poly-L-lysine-coated glass slides. They were then de-paraffinised in xylene and rehydrated through alcohol to distilled water. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 min at room temperature. After pressure cooking the sections in 10 mmol l⁻¹ EDTA (pH 8.0) for 3 min, they were incubated at room temperature with anti-WISP-1, WISP-2 and WISP-3 antibodies (1:50, 1:100 and 1:50 dilution, respectively) for 3 h, followed by incubation with HRP-conjugated secondary antibody. Development of slides was performed using peroxidase substrate (diaminobenzidine tetrahydrochloride) solution, followed by counterstaining with haematoxylin, dehydration in ethanol and clearing with xylene. Normal human mammary epithelium was used as positive control and normal gastric mucosa stained with PBS as primary antibody was used as a negative control. The degree of polyclonal WISP-1, WISP-2 and WISP-3 antibody reactivity was scored by assessing the percentage of stained

---

### Table 1. Association of WISP-1, WISP-2 and WISP-3 mRNA expression with clinicopathological parameters in GC patients

| Clinical pathological parameters | WISP-1 | | | WISP-2 | | | WISP-3 | |
|----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|
|                                   | Cases  | N⁰     | Median (Q1, Q3) | P      | Cases  | N⁰     | Median (Q1, Q3) | P      |
| **Tissue sample**                 |        |        |                  |        |        |        |                  |        |
| Normal                           | 158    | 31     | (0.0243, 0.135) | 0.0642 | 182    | 7      | 1.3 (0.1589) | 0.0028**|
| Tumour                           | 260    | 64     | (0.0501)        |        | 320    | 4      | 4.9 (0.28)   |        |
| **Gender**                       |        |        |                  |        |        |        |                  |        |
| Male                             | 185    | 46     | (0.0126)        |        | 230    | 1      | 4.9 (0.155)  |        |
| Female                           | 75     | 18     | (0.0501)        |        | 90     | 3      | 5.1 (0.2696) |        |
| **Infiltration depth**           |        |        |                  |        |        |        |                  |        |
| T1 + T2                          | 40     | 2      | (0.0611)        |        | 41     | 1      | 15.9 (1.1169) |        |
| T3 + T4                          | 213    | 61     | (0.0130)        |        | 271    | 3      | 4.6 (1.589)  |        |
| **Lymph node status**            |        |        |                  |        |        |        |                  |        |
| N0                               | 55     | 16     | (0.0468)        |        | 69     | 2      | 14.8 (4.834) |        |
| N1 + 2 + 3                       | 201    | 46     | (0.0126)        |        | 133    | 1      | 4.0 (1.55)   |        |
| **M-staging**                    |        |        |                  |        |        |        |                  |        |
| M0                               | 227    | 55     | (0.0269)        |        | 278    | 4      | 5.4 (2.631)  |        |
| M1                               | 33     | 8      | (0.0111)        |        | 41     | 0      | 4.0 (4.45)   |        |
| **TNM staging**                  |        |        |                  |        |        |        |                  |        |
| TNM1 + 2                         | 70     | 15     | (0.0759)        |        | 133    | 1      | 9.1 (2.924)  |        |
| TNM3 + 4                         | 183    | 47     | (0.0110)        |        | 228    | 2      | 15.9 (1,777) |        |
| **Differentiation**              |        |        |                  |        |        |        |                  |        |
| High                             | 5      | 1      | (0.0123)        |        | 6      | 0      | 0.9 (0.529)  |        |
| High–medium                      | 52     | 10     | (0.0230)        |        | 60     | 2      | 5.3 (1.764)  |        |
| Medium                           | 61     | 21     | (0.0737)        |        | 81     | 1      | 15.9 (2.496) |        |
| Medium–low                       | 112    | 26     | (0.082)         |        | 137    | 1      | 5.2 (2.784)  |        |
| **Clinical outcome**             |        |        |                  |        |        |        |                  |        |
| Alive                            | 106    | 28     | (0.0440)        |        | 133    | 1      | 9.1 (2.924)  |        |
| Died                             | 152    | 35     | (0.071)         |        | 184    | 3      | 3.8 (1.417)  |        |
| Disease-free                     | 94     | 25     | (0.0440)        |        | 118    | 1      | 10.5 (2.955) |        |
| metastasis                       | 12     | 3      | (0.0837)        |        | 15     | 0      | 1.9 (1.316)  |        |
| Died of GC                       | 152    | 35     | (0.071)         |        | 184    | 3      | 3.8 (1.417)  |        |

Abbreviations: GC = gastric cancer; TNM = tumour node metastasis; WISP = Wnt-inducted secreted protein. Notes: N⁰ = missing cases.

*Compared with ‘High–medium’.

bCompared with ‘Disease Free’.

*P<0.05.

**P<0.01.
adenocarcinoma cells in the section. In this study, expression in GC specimens was defined as ‘negative’ (0–20% stained cells) or ‘positive’ expression (>20% stained cells). Slides were analysed independently by two observers using light microscopy. Photographs were recorded on an Olympus CKX41 microscope. For representative images of WISP-2, see Figure 1.

Construction of anti-human WISP-2 ribozyme and knockdown (kd) of WISP-2 in GC cell lines. Anti-human WISP-2 hammer-head ribozyme sequences were designed based on the secondary structure of the mRNA generated using Zuker’s RNA Mfold programme (Zuker, 2003). The ribozymes were synthesised and cloned into pEF6/V5-His-TOPO plasmid vector and then ribozyme transgenes and control plasmids were transfected into AGS and HGC27 cells, using an electroporator (Easyjet Plus; EquiBio, Ltd., Kent, UK). Stable transfectants were obtained after 2 weeks of selection using 5–7.5 μg ml⁻¹ blasticidin. We also used a plasmid in which the Ribozyme transgene was inserted in the ‘wrong’ direction (that is, sense direction) and a control. Multiple clones were combined and grown as a new population of sublines. RT-PCR, Q-RT-PCR and western blotting were used to verify the efficiency of knock down on the new sublines. Oligo sequences are given in Supplement 1.

In vitro cell growth assay. A standard procedure was used as previously described (Jiang et al, 2005). Gastric cells were plated into a 96-well plate (3000 cells per well). Cells were fixed in 4% formalin after 1, 3 and 5 days. The cells were then stained with 0.5% (w/v) crystal violet for half an hour. Following washing, stained crystal violet was extracted with 10% (v/v) acetic acid. Absorbance was determined at a wavelength of 540 nm using a spectrophotometer (Elx800; Bio-Tek, Bedfordshire, UK). Growth rate was calculated as follows:

\[
\text{Growth rate on day } n = \frac{\text{absorbance on day } n}{\text{absorbance on day } 1} \\
\]

In vitro cell-matrix adhesion assay. A total of 40,000 cells were added to each well of a 96-well plates previously prepared by coating with Matrigel (5 μg per well). The cells were incubated at 37°C in 5% CO₂ for 40 min and the medium was then discarded. Nonadherent cells were washed off using BSS buffer. The remaining cells were then fixed in 4% formaldehyde for 5 min. After further washing, cells were stained with crystal violet, and the number of adherent cells was then counted.

In vitro invasion assay. This was carried out as previously reported and modified in our laboratory (Jiang et al, 1995). Transwell inserts with 8 μm pore size were coated with 50 μg Matrigel and air-dried. The Matrigel was rehydrated before use. A total of 25,000 cells were seeded to each well and after 72 h, cells that had migrated through the matrix and pores were fixed with 4% formalin, stained in crystal violet and counted.

In vitro wounding assay. Cells were seeded into a 24-well plate at a density of 200,000 per well and allowed to form a monolayer, which was then scraped to create a wound about 200 μm wide (Jiang et al, 1999). Migration of the cells at wounding edges was monitored and photographs were taken at 0.25, 1, 2, 3 and 4 h after wounding. Migration distances were measured using Image J software (www.ImageJ.net).

The effects of different small inhibitors on the cell motility. ECIS (Electric Cell-Substrate Impedance Sensing) is a novel method used as an alternative to conventional functional assays. It works with an array of 96 wells, each containing a gold electrode. These measure the current and voltage across this electrode, calculating the impedance and resistance. From the impedance changes, effects on cell attachment and motility can be examined (Keese et al, 2004). Using 96W1E+ array, cell adhesion and wounding assay were also performed with ECIS. A total of 40,000 cells diluted in 200 μl of DMEM were seeded into each ECIS plate well, and treated with a protein of interest. In this study, we treated the cells with different concentrations of PLC inhibitor U73122, FAK inhibitor PF573228 and INK inhibitor SP100625. Inhibitors were first dissolved in DMSO (1 mM) and then diluted with serum-free medium to different concentrations. For the control group, an identical volume of serum-free medium was added into wells. The array was then placed into an ECIS CO₂ incubator, which was connected to the ECIS Model 9600 Controller. Cell adhesiveness was assessed within the first 40 min and the electric wound was set at the 14th hour when the resistance reached maximum levels and migration data could be gathered continuously for 6 h.

Quantitative analysis for EMT markers in cell lines. The levels of mRNA expression of EMT markers, E-cadherin, N-cadherin, Twist, Slug and Vimentin were determined by real-time quantitative PCR and RT-PCR in WISP-2 kd and control cells. GAPDH was used as an internal control. Primer details are given in Supplement 1.

Expression and activity of metalloproteinases (MMPs). The levels of mRNA expression of MMP1, MMP2, MMP3, MMP7 and MMP9 were determined by RT-PCR in WISP-2 kd and control cells. To test the activity of type IV collagens MMP2 and MMP9, which are of the most important type of MMPs, 1 × 10⁶ cells were seeded into a 25-cm² culture flask and incubated overnight. Following incubation, cells were washed once with sterile 1x BSS followed by a wash with serum-free DMEM and then either incubated in serum-free DMEM control or treated medium for 6 h. In this study, we treated cells with 200 μM of TNF or ERKII small inhibitors, respectively. After 6 h, the conditioned medium was collected and samples were prepared in non-reducing sample buffer and separated using SDS-PAGE gels containing 1% gelatin (Sigma-Aldrich Inc.). After renaturing for 1 h at room temperature in washing buffer containing 2.5% Triton X-100 and 0.02% Na₂SO₄, the gels were then incubated at 37°C in incubation buffer for 36 h. Following incubation, the gels were stained with Coomassie blue for 1 h and washed in destaining buffer for another 1 h. The gels were analysed using densitometry.

Statistical analysis. Statistical analysis was performed using SPSS18 (SPSS Inc., Chicago, IL, USA). IHC data were cross-tabulated and a χ² test was performed. The association of staining for WISP-1, WISP-2 and WISP-3 in GCs with patient survival was evaluated using life tables constructed from survival data with Kaplan–Meier plots and analysed using log-rank statistics. Overall survival was measured from date of initial surgery to date of death, counting death from any cause as the end point, or the last date of information as the end point if no event was documented. The association of the expression of WISPs and EMT markers was analysed using Spearman Rank Order Correlation analysis. Other data were analysed using Student’s t-test for normally distributed data and Mann–Whitney U-test for non-normally distributed data. Each assay was performed at least three times. P-value <0.05 was considered statistically significant.

RESULTS

Expression of WISPs mRNAs, proteins and EMT markers in gastric tissues. When analysed by Q-RT-PCR, WISP-2 transcripts showed a higher level in tumours than in normal tissues (P = 0.0028) but WISP-1 and WISP-3 showed no differences (P = 0.0642 and P = 0.9076, respectively). However, levels of the WISP-1 were highly expressed in tumours of patients without distant metastasis at diagnosis than those with (P = 0.0168). Levels of the WISP-2 transcript were found significantly higher in TNM1 and TNM2 stage tumours (P = 0.0249) than in TNM3 and TNM4 stages and also higher in T1 and T2 than in T3 and T4.
Figure 1. WISP-2 protein expression in primary gastric cancer and Kaplan–Meier survival curve for WISP-2 expression in gastric cancer tissues. In gastric cancer, WISP-2 protein was immunoreactive in the cytoplasm of malignant cells. The intensity of WISP-2 immunoreactivity was remarkably higher in primary gastric carcinoma when compared with matched normal mucosa. (A and B) Images of WISP-2 staining in normal gastric mucosa showed absent or weak cytoplasmic reactivity. (C and D) Images of WISP-2 staining in diffuse gastric cancer and (E and F) in adenocarcinoma. (G) Positive control in breast epithelium, and (H) negative control using PBS as primary antibody in normal gastric mucosa. (I) Kaplan–Meier survival analysis displaying relationship between the transcript levels of WISP-2 and overall survival, WISP-2 (+) represents the patients with higher expression of WISP-2 (N = 174), WISP-2 (−) represents the patients with lower expression WISP-2 (N = 173). (J) Kaplan–Meier survival analysis displaying the relationship between the transcript levels of WISP-2 and disease-free survival. WISP-2 (+) represents the patients with higher expression of WISP-2 (N = 133), WISP-2 (−) represents the patients with lower expression of WISP-2 (N = 171). WISP-2 expression is positively correlated with the survival of gastric cancer patients, either in overall survival or in disease-free survival (P<0.05, respectively).
Expression levels of WISP proteins were analysed using immunohistochemical method. All three proteins were found to be located in the cytoplasmic region. Shown in Figure 1 are representative images for WISP-2, in which the protein staining in normal gastric tissues was largely negative (Figure 1A and B). In a clear contrast, the staining in gastric tumour tissues was highly positive and was clearly cytoplasmic. Semiquantitative analyses have shown that in line with Q-PCR findings, no difference was observed in normal gastric tissues versus tumour tissues showing positive WISP-2 protein staining, compared with poorly differentiated tumours showing positive staining in poorly differentiated tumours (P = 0.024; Figure 1 and Table 2). Using Kaplan–Meier plot and log rank test, WISP-2 was found to be positively correlated with overall survival (P = 0.032, vs with WISP-2-negative tumours) and a longer disease-free survival (P = 0.039 vs with negative tumours; Figure 2 and J).

Table 2. Association of WISP-1, WISP-2 and WISP-3 protein expression with clinicopathological parameters in gastric cancer patients

| Variables | WISP-1 expression | | WISP-2 expression | | WISP-3 expression |
|-----------|-----------------|---|-----------------|---|-----------------|
| | Cases | WISP-1 − (n = 123) | WISP-1 + (n = 114) | P | Cases | WISP-2 − (n = 128) | WISP-2 + (n = 101) | P | Cases | WISP-3 − (n = 56) | WISP-3 + (n = 185) | P |
| Gender | | | | | | | | | | | | |
| Male | 172 | 89 | 83 | 0.938 | 161 | 87 | 74 | 0.384 | 174 | 39 | 135 | 0.626 |
| Female | 65 | 34 | 31 | | 68 | 41 | 27 | | 67 | 17 | 50 | |
| Age (years) | | | | | | | | | | | | |
| ≤ 60 | 114 | 60 | 54 | | 114 | 61 | 47 | | 117 | 31 | 86 | 0.198 |
| > 60 | 122 | 61 | 61 | 0.686 | 113 | 59 | 54 | 0.32 | 123 | 24 | 99 | |
| Depth of wall invasion | | | | | | | | | | | | |
| T1 + T2 | 35 | 20 | 15 | | 35 | 20 | 15 | | 38 | 7 | 31 | 0.499 |
| T3 + T4 | 190 | 95 | 95 | 0.437 | 182 | 102 | 80 | 0.904 | 192 | 45 | 147 | |
| Differentiation | | | | | | | | | | | | |
| Well and moderate | 40 | 16 | 24 | | 37 | 14 | 23 | | 41 | 8 | 33 | 0.562 |
| Poorly | 146 | 80 | 66 | 0.097 | 140 | 82 | 58 | 0.024* | 147 | 35 | 112 | |
| Lymph node metastasis | | | | | | | | | | | | |
| Negative | 46 | 26 | 20 | | 47 | 30 | 17 | | 45 | 31 | 14 | 0.307 |
| Positive | 173 | 85 | 88 | 0.373 | 164 | 88 | 76 | 0.216 | 121 | 65 | 56 | |
| Liver metastasis | | | | | | | | | | | | |
| M0 | 185 | 94 | 91 | 0.808 | 179 | 97 | 82 | 0.184 | 190 | 41 | 149 | 0.415 |
| M1 | 35 | 17 | 18 | | 33 | 22 | 11 | | 36 | 10 | 26 | |
| Vascular invasion | | | | | | | | | | | | |
| V(−) | 126 | 69 | 57 | | 121 | 75 | 46 | | 126 | 31 | 95 | 0.651 |
| V(+) | 109 | 53 | 56 | 0.348 | 106 | 53 | 53 | 0.069 | 113 | 25 | 88 | |
| TNM stages | | | | | | | | | | | | |
| I + II | 72 | 39 | 33 | 0.441 | 72 | 43 | 29 | | 78 | 17 | 61 | 0.8 |
| III + IV | 144 | 70 | 74 | | 137 | 74 | 63 | 0.43 | 146 | 34 | 112 | |

Abbreviations: TNM — tumour node metastasis; WISP — Wnt-inducted secreted protein.

*P < 0.05.
their pEF counterparts (13.199 ± 5.63 vs 23.961 ± 4.11, P < 0.001 and 15.939 ± 4.95 ± 2.51 vs 27.635, P < 0.001, respectively). WISP-2 kd resulted in a dramatic increase of invasiveness of AGS (133.58 ± 18.8 vs 207.36 ± 19.71, P < 0.01) and HGC27 (88.66 ± 27.43 vs 153.66 ± 10.01, P < 0.01) cells (Figure 2F) compared with controls. WISP-2kd also resulted in an increase in motility of AGS (105.49 ± 22.34 vs 145.16 ± 18.66, P < 0.01) and HGC27 (127.53 ± 32.76 vs 161.39 ± 40.38, P < 0.05) cells (data not shown). However, kd of WISP-2 exhibited a relatively weak impact on cell matrix adhesion. The number of cells adherent to Matrigel (STK870702, Vitas-M Laboratory Ltd; 1.12 ± 0.05) on cell matrix adhesion. The number of cells adherent to Matrigel (STK870702, Vitas-M Laboratory Ltd; 1.12 ± 0.05, respectively). Expression of Slug was found to have no statistical significance compared with the control group (0.05). A significant decrease was also observed in HGC27 WISP-2 kd cells (Figure 2G, P < 0.05, respectively).

Cell adhesion was also analysed using ECIS. After 40 min of adhesion, there was no significant difference in the resistance between WISP-2 kd and pEF controls in both cells (Figure 2H, P > 0.05, respectively). After treatment with small PLC-γ inhibitor (STK870702, Vitas-M Laboratory Ltd; 1.12 μM) and a genetic PLC inhibitor (UTS122, Tocris Bioscience; 0.75 μM), the motility of HGC27 WISP-2 kd decreased compared with control cells (P < 0.05). A significant decrease was also observed in HGC27 WISP-2 kd cells treated with JNKKII (1.5 μM). However, FAK small inhibitors (1.5 μM) and N-WASP small inhibitors (1.5 μM, data not shown) did not change the effect on both cell lines (P > 0.05; Figure 3A ~ D).

WISP-2 kd resulted in increased enzymatic activity of MMPs via JNK and/or ERK pathways. MMPs are key proteins implicated in ECM remodelling and degradation by metastatic cells (Coussens et al, 2002). WISP-2 kd resulted in an upregulation of MMP9 in AGS WISP-2 kd cells, and MMP9 and MMP2 in HGC27 WISP-2 kd cells, which were consistent with increased invasiveness in both cells. We further treated both cells with 200 nM JNKKII and ERKII small inhibitor. The elevated MMP9 activity in AGS WISP-2 kd cells was reduced after treatment with ERK and JNK inhibitors. However, the elevated MMP9 and MMP2 activity in HGC27 WISP-2 kd cells were reduced only by JNK inhibitor, but not by ERK inhibitor (Figure 4A and B).

WISP-2 kd influenced invasiveness of AGS cells treated with MMP inhibitors. Figure 4C and D shows AGS cells with WISP-2 kd after treatment with MMP9 inhibitor (Marimastat), which significantly decreased invasiveness (P = 0.025) compared with AGS WISP-2 kd cells with no treatment. The group treated with ARPI00 did not demonstrate a significant change on cell invasion compared with the control group (P > 0.05).

Expression of EMT markers in cell lines. The results showed that after WISP-2 kd, there was a significant decrease in expression of E-cadherin (P < 0.05) and an increase on the expression of Twist, N-cadherin and Vimentin (P < 0.01, P < 0.05 and P < 0.01, respectively). Expression of Slug was found to have no statistical difference between both cell lines. Representative images of Q-RT-PCR and RT-PCR verification of the expression of E-cadherin, N-cadherin, Twist, Slug and Vimentin in cell lines are shown in Figure 4E and F.

Table 3. Expression of the transcript of EMT markers Twist, Slug and E-cadherin in paired gastric tissues (n = 189)

|          | E-cadherin  | Twist     | Slug     |
|----------|-------------|-----------|----------|
| Normal   | 39 (3.284)  | 0.056 (0.027, 0.081) | 4.30 (2.35, 3.3) |
| Tumour   | 3 (0.53)    | 7 (9.39, 9.32)       | 7.8 (9.41, 5) |
| P value  |
|          | P < 0.0001  | P < 0.0001          | P = 0.0015 |

Abbreviation: EMT

DISCUSSION

Expression of WISP2 in gastric tissues of gastric cancer (GC).

The current study has provided new data that expression of WISP-2 at mRNA and protein levels are also aberrant in GC. Positive WISP-2 protein staining in GC are associated with a longer survival of the patients, and with differentiation of GC cells in gastric tumour, namely, 23 out of 37 (62%) positively stained in well/moderate differentiated tumours vs 58 out of 140 (41%) in poorly differentiated tumours. Thus, in line with the reports in breast cancer, the current study would support the hypothesis that WISP-2 is a candidate biomarker for disease progression in human GC.

Expression of WISP-2 and EMT in GC. Previous studies have suggested that WISP-2 is able to reverse some features of the EMT process (Dhar et al, 2007; Banerjee et al, 2008). These mechanisms are important in the invasion and metastatic growth of breast cancer cells. This study is the first to record the association of WISP mRNA and proteins expression with clinicopathological parameters and outcome in GC patients as well as the association with those of EMT markers. Here we show that WISP-2, but not WISP-1 or WISP-3, was inversely correlated with two of the EMT markers namely Twist and Slug. Twist and Slug are transcription EMT markers, the activation of which has
Figure 2. Verification of knockdown (kd) of WISP-2 in AGS and HGC27 cells. (A and B) Quantitative real-time PCR showing WISP-2 mRNA volume of five repeats, which was normalised against corresponding internal control (GAPDH). WISP-2 expression was decreased in AGS WISP-2 kd and HGC27 WISP-2 kd cells compared with corresponding pEF plasmid control cells and anti-sense plasmid control cells (*P<0.05). (C) RT-PCR showing reduced levels of WISP-2 mRNA in AGS WISP-2 kd and HGC27 WISP-2 kd cells compared with corresponding pEF plasmid control cells and sense plasmid control cells. (D) Decreased levels of WISP-2 protein (MW: 26KD) in AGS WISP-2 kd and HGC27 kd cells compared with corresponding pEF control cells are shown. (E left) After 5 days’ incubation, there was a significant increase in the AGS WISP-2 kd cells compared with the pEF controls and (E right) increase in the HGC27 WISP-2 kd cells compared with the pEF controls (***P<0.001). (F) Knockdown of WISP-2 caused a significant increase in the invasiveness of AGS WISP-2 kd cells compared with the AGS pEF cells (left) and HGC27 WISP-2 kd cells compared with the HGC27 pEF cells (right) (**P<0.01; right). (G) Representative images of cells following staining: after 45 min’ incubation on an artificial Matrigel basement membrane, the difference of the numbers of adherent cells was not significant in both AGS and HGC27 groups. (H) ECIS results also showed that there were no significant differences in adhesiveness in the first 45 min of knockdown groups than in pEF controls in AGS and HGC27 cells (P>0.05, respectively).
been shown to suppress the expression of E-cadherin (Yang et al., 2004; Lombaerts et al., 2006; Vesuna et al., 2008). We were the first to report a link between overexpression of Twist and Slug and long-term survival in patients with breast cancer (Martin et al., 2005). Slug has been reported to be overexpressed in GC similar to that seen in the present study (Rosivatz et al., 2002; Castro Alves et al., 2007). Thus, the observations on the clinical cohort suggest that low levels of WISP-2 are linked to raised Twist and Slug, which in turn lead to a reduction in E-cadherin expression.

Further supporting information for the WISP-2/EMT link comes from the in vitro experiments of this study. At the cellular level, knockdown of WISP-2, in both AGS and HGC27 cell lines, led to increased cell proliferation, motility and invasiveness, hallmarks of EMT in cells including cancer cells. At transcription and translation levels, WISP-2 knockdown in GC cells triggers an upregulation of Twist, N-cadherin and Vimentin, markers of mesenchymal genotype (Zeisberg and Neilson, 2009). Collectively, these results suggest that WISP-2 is an EMT regulator and that WISP-2 expression supports an epithelial phenotype. This link has provided a plausible explanation for WISP-2 to be potential suppressor of EMT (or an inducer of MET). The suggested link and interaction pathway are summarised in Figure 5.

**WISP-2 and expression of MMPs, a role for the JNK pathway.**

Suppression of WISP-2 expression leads to the upregulation of the matrix MMPs, MMP2 and MMP9, which are often found to be highly expressed in the invasive breast cancer phenotype (Banerjee et al., 2008). The expression of MMP-1, MMP-2, MMP-9 and MMP-13 has been shown to be linked to the aggressiveness of tumours and their expression is mediated by p38 in various tissues including prostate, breast, bladder, liver and skin keratinocyte cell lines. Several reports have shown that MMP9 is upregulated by the ERK signalling pathway in different human cells (Li et al., 2003). However, the mechanism by which WISP-2 deficiency enhances the invasiveness of cancer cells has not been elucidated and remains poorly understood (Vandooren et al., 2013). In the present study, we have discovered that WISP-2 may suppress the expression of MMPs as well as activities of MMP2 and MMP9 in GC cells. Our study also describes a role for JNK and ERK in this regulation, partly owing to the observation that treatment with JNKII and ERKII small inhibitors blocked the effects seen by knocking down WISP2, indicating that the JNK pathway is suppressed by WISP-2. Our results echo a recent report in which Twist has been linked to the expression of MMP1 (Weiss et al., 2012). It is thus indicated that loss of WISP-2 results in activation of MMPs in cancer cells (Figure 5).

**WISP-2 has an intimate link with phospholipase C-γ and JNK-mediated cell functions.** Phospholipase C-γ is a critical molecule in growth factor-dependent signalling transduction, and its expression is related with cell motility and tumorigenesis (Jones et al., 2005; Davies et al., 2008; Zhang et al., 2011). PLCγ1 activation induces hydrolysis of phosphatidylinositol-4,5-bisphosphate to form the second messengers diacylglycerol and inositol-1,4,5-trisphosphate, which in turn activate protein kinase C and intracellular calcium mobilisation, respectively. Through both events, PLCγ1 is involved in a number of physiological processes...
including cell proliferation, migration, survival and death (Lattanzio et al., 2013). It has also been reported that individually or combined inhibition of PLC-\(\gamma\) and c-Src could block EGFR-mediated HNSCC cell invasion (Nozawa et al., 2008). The PLC-\(\gamma\) inhibitor STK870702 impedes the DNA synthesis of the breast cancer cell lines investigated in the nanomolar range as a consequence of anti-proliferative activity. It has been shown that cell cycle arrest is instigated in the G2/M phases. Furthermore, morphology and motility were severely affected by STK870702 in the MDA-MB-231 breast tumour cell line (Leung et al., 2014). In our study, inhibition of PLC-\(\gamma\) by STK870702 and a less specific inhibitor U73122 could block WISP-2 knockdown-mediated HGC27 cell migration, which suggests that WISP-2 may suppress HGC27 cell migration partly via suppressing the PLC-\(\gamma\) pathway (Figure 5). However, the role of PLC-\(\gamma\) in cancer is not entirely clear. Although PLC-\(\gamma\) has been indicated in the regulation of cell migration and in tumour progression in some cases, some of the recent reports have shown that it can play a role in suppressing tumour growth. Capietto et al. (2013) have reported that PLC-\(\gamma\)-deficiency would result in faster tumour growth, possibly by reducing the population of myeloid-derived suppressor cells, which in turn promote tumour growth. The authors argued that this is
likely due to a reduction of β-catenin after inducing PLC-γ2 deficiency. Reduction of both PLC-γ and β-catenin has been observed in the myeloid-derived suppressor cells in patients with cancer (Capietto et al., 2013). In addition, the link between PLC-γ, cell migration and cell adhesion appears to have association with the balance and compensation between the isoforms of PLC-γ as well as choline metabolism (Beloueche-Babari et al., 2009). Despite these evidence, one has to bear that the isoforms of PLC-γ, namely PLC-γ1 and PLC-γ2, can have different and sometimes contrasting effect in different cells and cell models. Thus, the relationship between WISP-2 and PLC-γ, its isoforms and indeed the role of PLC-γ in cancer would require further investigation. We are currently exploring the potential link between WISP2, β-catenin and PLC-γ in this connection.

Sengupta et al. (2006) found that the upregulation of WISP-2 by phorbol ester is mediated through a complex protein kinase Cz-MAPK/ERK and MAPK/JNK signalling pathway, which leads to growth stimulation of MCF-7 breast tumour cells. However, in our study, JNK may act as a downstream molecule of WISP-2 in the cytoplasm. JNK belongs to the JNK P38 MAP kinase pathway. In non-stimulated cells, JNK2 seems to mainly target c-Jun for degradation. However, in stimulated cells, JNK1 phosphorylates and stabilises c-Jun resulting in activation of transcription of the target genes. The effects of JNK small inhibitor on WISP-2 knockdown-mediated HGC27 cell migration indicate that WISP-2 may suppress HGC27 cell migration via suppressing JNK and its downstream pathway. However, the exact mechanism and other unknown interacting molecules involved in this effect require further investigation.

Overall, the current study suggests the clinical significance of WISP-2 in gastric tumour progression in that WISP-2 is positively correlated with the clinical features and the survival of the patients with GC. Moreover, this study unveiled a molecular mechanism of regulation of WISP-2 expression in GC metastasis, namely that WISP-2 is a critical negative regulator of growth, motility and invasion in GC cells via key signalling pathways involving JNK, ERK and PLC-γ, which lead to the regulation of the EMT process. Taken together, this study shows that WISP-2 is a potential tumour suppressor. It is plausible that the reactivation of WISP-2 into invasive/metastatic GCs alone or in combination of current therapeutic regimens may provide a unique alternative strategy to existing GC therapy.

**ACKNOWLEDGEMENTS**

We thank Cancer Research Wales, Ser Cymru Welsh Life Science Network and the Albert Hung Foundation for supporting our work. This project was also funded by the ‘Young Scientific Elite Project of Educational Bureau, Inner Mongolia Autonomous Region, China, 2012’ (No. NYT-12-B21) and ‘Great Project of the Affiliated Hospital of Inner Mongolia Medical University,
The authors declare no conflict of interest.

REFERENCES

Banerjee S, Dhar G, Haque I, Kambhampti S, Mehta S, Sengupta K, Tawfic O, Phillips TA, Banerjee SK (2008) CCN5/ WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 68: 7606–7612.

Banerjee S, Saxena N, Sengupta K, Tawfic O, Mayo MS, Banerjee SK (2003) WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 5: 63–73.

Banerjee S, Saxena NK, Dhar K, Banerjee SK (2005) Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha- positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res 3: 151–162.

Banerjee SK, Banerjee S (2012) CCN5/WISP-2: a micromanager of breast cancer progression. J Cell Commun Signal 6: 63–71.

Beloueche-Babari M, Joanne C, Peak JC, Jackson LE, Tiet MY, Leach MO, Eccles SA (2009) Changes in choline metabolism as potential biomarkers of phospholipase C1 inhibition in human prostate cancer cells. Mol Cancer Ther 8: 1305–1311.

Bork P (1993) The modular architecture of a new family of growth regulators associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 68: 7606–7612.

Calvisi DF, Conner EA, Ladu S, Lemmer ER, Factor VM, Thorgeirsson SS (2007) Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 65: 5043–5048.

Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K, Mansel RE (2005) Targeting matrixins and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 11: 6012–6019.

Davies G, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MCA (1995) Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 65: 5043–5048.

Davies SR, Davies ML, Sanders A, Parr C, Torkington J, Jiang WG (2010) Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head metastasis (review). J Cell Sci 123: 4336–4344.

Dharmarajan AJ, Dobran RA, Joosse SA, Voss KC, Kligerman MD, Liao C, Powers ME, Gurney JG, Mesirow J, et al. (2008) Inhibition of nuclear factor-{kappa}B abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 14: 4336–4346.

Dharmarajan AJ, Dobran RA, Joosse SA, Voss KC, Kligerman MD, Liao C, Powers ME, Gurney JG, Mesirow J, et al. (2008) Inhibition of nuclear factor-{kappa}B abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 14: 4336–4346.

Dharmarajan AJ, Dobran RA, Joosse SA, Voss KC, Kligerman MD, Liao C, Powers ME, Gurney JG, Mesirow J, et al. (2008) Inhibition of nuclear factor-{kappa}B abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 14: 4336–4346.
Russo JW, Castellot JJ (2010) CCN5: biology and pathophysiology. J Cell Commun Signal 4: 119–130.
Sengupta K, Banerjee S, Dhar K, Saxena NK, Mehta S, Campbell DR, Banerjee SK (2006) WISP-2/CCN5 is involved as a novel signaling intermediate in phorbol ester-protein kinase Calpha-mediated breast tumor cell proliferation. Biochemistry 45: 10698–10709.
Soon LI, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM (2003) Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 278: 11465–11470.
Tian C, Zhou ZG, Meng WJ, Sun XF, Yu YY, Li L, Luo HZ, Yang L, Zhou B, Gu J (2007) Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J Gastroenterol 13: 3878–3882.
Vandooren J, Geurts N, Martens E, Van den Steen PE, Opdenakker G (2013) Zymography methods for visualizing hydrolytic enzymes. Nat Methods 10: 211–220.
Vesuna F, van Diest P, Chen JH, Raman V (2008) Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367: 235–241.
Weiss MB, Abel EV, Mayberry MM, Basile K, Berger AC, Aplin AE (2012) TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res 72: 6382–6392.
Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61: 8917–8923.
Yang J, Mani SA, Donaher JL, Ramasawmy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927–939.
Zeisberg M, Neilon EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: c1429–c1437.
Zhang P, Zhao Y, Zhu X, Sedwick D, Zhang X, Wang Z (2011) Cross-talk between phospho-STAT3 and PLCgamma1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res 9: 1418–1428.
Zoubine MN, Banerjee S, Saxena NK, Campbell DR, Banerjee SK (2001) WISP-2: a serum-inducible gene differentially expressed in human normal breast epithelial cells and in MCF-7 breast tumor cells. Biochem Biophys Res Commun 282: 421–425.
Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406–3415.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)